Daunomycin
Acute Myeloid Leukemia, MLL Gene Rearrangement
National Cancer Institute (NCI)Small moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
14 Active assets in the Acute Myeloid Leukemia, MLL Gene Rearrangement cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cytarabine National Cancer Institute (NCI) | Phase 2 | B |
Revumenib National Cancer Institute (NCI) | Phase 2 | B |
Hydrocortisone Children's Oncology Group | Phase 2 | CCC |
Vincristine Sulfate Children's Oncology Group | Phase 2 | CCC |
Methotrexate Children's Oncology Group | Phase 2 | CCC |
View all 14 →
Same molecule, other indications
Daunomycin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →